Literature DB >> 18294332

A well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patient.

Hélène Blasco, Michéle Boisdron-Celle, Philippe Bougnoux, Gilles Calais, Jean-François Tournamille, Joseph Ciccolini, Elisabeth Autret-Leca, Chantal Le Guellec.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18294332      PMCID： PMC2485217          DOI： 10.1111/j.1365-2125.2008.03106.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  21 in total

1.  Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency.

Authors:  A B van Kuilenburg; E W Muller; J Haasjes; R Meinsma; L Zoetekouw; H R Waterham; F Baas; D J Richel; A H van Gennip
Journal:  Clin Cancer Res       Date:  2001-05       Impact factor: 12.531

2.  Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer.

Authors:  Josefa Salgado; Natalia Zabalegui; Carmen Gil; Ignacio Monreal; Javier Rodríguez; Jesús García-Foncillas
Journal:  Oncol Rep       Date:  2007-02       Impact factor: 3.906

3.  5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency.

Authors:  M Boisdron-Celle; G Remaud; S Traore; A L Poirier; L Gamelin; A Morel; E Gamelin
Journal:  Cancer Lett       Date:  2006-10-24       Impact factor: 8.679

4.  Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.

Authors:  M Raida; W Schwabe; P Häusler; A B Van Kuilenburg; A H Van Gennip; D Behnke; K Höffken
Journal:  Clin Cancer Res       Date:  2001-09       Impact factor: 12.531

5.  Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity.

Authors:  Nicolas Magné; Marie-Christine Etienne-Grimaldi; Laurent Cals; Nicole Renée; Jean-Louis Formento; Mireille Francoual; Gérard Milano
Journal:  Br J Clin Pharmacol       Date:  2007-03-01       Impact factor: 4.335

6.  Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule.

Authors:  C J van Groeningen; H M Pinedo; J Heddes; R M Kok; A P de Jong; E Wattel; G J Peters; J Lankelma
Journal:  Cancer Res       Date:  1988-12-01       Impact factor: 12.701

7.  Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5'-deoxy-5-fluorocytidine formation.

Authors:  Toshiki Tabata; Miki Katoh; Shogo Tokudome; Masakiyo Hosakawa; Kan Chiba; Miki Nakajima; Tsuyoshi Yokoi
Journal:  Drug Metab Dispos       Date:  2004-07       Impact factor: 3.922

Review 8.  Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration.

Authors:  Hany Ezzeldin; Robert Diasio
Journal:  Clin Colorectal Cancer       Date:  2004-09       Impact factor: 4.481

Review 9.  Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.

Authors:  André B P van Kuilenburg
Journal:  Eur J Cancer       Date:  2004-05       Impact factor: 9.162

10.  Association of intratumoral pharmacokinetics of fluorouracil with clinical response.

Authors:  C A Presant; W Wolf; V Waluch; C Wiseman; P Kennedy; D Blayney; R R Brechner
Journal:  Lancet       Date:  1994-05-14       Impact factor: 79.321
View more
  3 in total

Review 1.  Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.

Authors:  Maarten J Deenen; Annemieke Cats; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2011-05-31

2.  Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil.

Authors:  Saranya Kodali; Venu Bathini; Paul Rava; Eswar Tipirneni
Journal:  J Gastrointest Cancer       Date:  2017-03

3.  Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy.

Authors:  Laia Paré; David Paez; Juliana Salazar; Elisabeth Del Rio; Eduardo Tizzano; Eugenio Marcuello; Montserrat Baiget
Journal:  Br J Clin Pharmacol       Date:  2010-08       Impact factor: 4.335
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.